PubRank

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

Clinical Trial ID NCT00625898

PubWeight™ 18.02‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00625898

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
2 Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2012 1.23
3 Treatment of HER2-positive breast cancer. Breast 2013 1.09
4 Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010 1.05
5 Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 2011 1.03
6 Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol 2012 1.03
7 A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011 1.01
8 Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014 0.96
9 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
10 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
11 Antiangiogenic therapy for breast cancer. Breast Cancer Res 2010 0.90
12 Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab. Curr Oncol 2012 0.89
13 Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 2013 0.83
14 Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009 0.80
15 Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiol Oncol 2014 0.77
16 Adjuvant trastuzumab: does time really matter? Oncologist 2013 0.75
Next 100